| References |
1. Khallou J, et al. Metabolism and time-course excretion of murideoxycholic acid, a 6 beta-hydroxylated bile acid, in humans. J Hepatol. 1993;17(3):364-372. 2. Bullich-Vilarrubias C, Romaní-Pérez M, López-Almela I, Rubio T, García CJ, Tomás-Barberán FA, Sanz Y. Nav1.8-expressing neurons control daily oscillations of food intake, body weight and gut microbiota in mice. Commun Biol. 2024 Feb 22;7(1):219. 3. Kuang J, Wang J, Li Y, Li M, Zhao M, Ge K, Zheng D, Cheung KCP, Liao B, Wang S, Chen T, Zhang Y, Wang C, Ji G, Chen P, Zhou H, Xie C, Zhao A, Jia W, Zheng X, Jia W. Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis. Cell Metab. 2023 Oct 3;35(10):1752-1766.e8. 4. Shen S, Huang D, Qian S, Ye X, Zhuang Q, Wan X, Dong Z. Hyodeoxycholic acid attenuates cholesterol gallstone formation via modulation of bile acid metabolism and gut microbiota. Eur J Pharmacol. 2023 Sep 15;955:175891. 5. Li J, Chen Y, Li R, Zhang X, Chen T, Mei F, Liu R, Chen M, Ge Y, Hu H, Wei R, Chen Z, Fan H, Zeng Z, Deng Y, Luo H, Hu S, Cai S, Wu F, Shi N, Wang Z, Zeng Y, Xie M, Jiang Y, Chen Z, Jia W, Chen P. Gut microbial metabolite hyodeoxycholic acid targets the TLR4/MD2 complex to attenuate inflammation and protect against sepsis. Mol Ther. 2023 Apr 5;31(4):1017-1032. |
